Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Phosphoinositide 3-kinases (PI3Ks) are promising targets for therapeutic development in cancer. The class I PI3K isoform p110α has received considerable attention in oncology because the gene encoding p110α (PIK3CA) is frequently mutated in human cancer. However, little is known about the function o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4051752?pdf=render |
| _version_ | 1818010574344159232 |
|---|---|
| author | Sung Su Yea Lomon So Sharmila Mallya Jongdae Lee Kamalakannan Rajasekaran Subramaniam Malarkannan David A Fruman |
| author_facet | Sung Su Yea Lomon So Sharmila Mallya Jongdae Lee Kamalakannan Rajasekaran Subramaniam Malarkannan David A Fruman |
| author_sort | Sung Su Yea |
| collection | DOAJ |
| description | Phosphoinositide 3-kinases (PI3Ks) are promising targets for therapeutic development in cancer. The class I PI3K isoform p110α has received considerable attention in oncology because the gene encoding p110α (PIK3CA) is frequently mutated in human cancer. However, little is known about the function of p110α in lymphocyte populations that modulate tumorigenesis. We used recently developed investigational inhibitors to compare the function of p110α and other isoforms in natural killer (NK) cells, a key cell type for immunosurveillance and tumor immunotherapy. Inhibitors of all class I isoforms (pan-PI3K) significantly impaired NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity against tumor cells, whereas p110α-selective inhibitors had no effect. In NK cells stimulated through NKG2D, p110α inhibition modestly reduced PI3K signaling output as measured by AKT phosphorylation. Production of IFN-γ and NK cell-derived chemokines was blocked by a pan-PI3K inhibitor and partially reduced by a p110δinhibitor, with lesser effects of p110α inhibitors. Oral administration of mice with MLN1117, a p110α inhibitor in oncology clinical trials, had negligible effects on NK subset maturation or terminal subset commitment. Collectively, these results support the targeting of PIK3CA mutant tumors with selective p110α inhibitors to preserve NK cell function. |
| first_indexed | 2024-04-14T05:57:05Z |
| format | Article |
| id | doaj.art-78bce9d364664089b609f2dac044ac14 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T05:57:05Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-78bce9d364664089b609f2dac044ac142022-12-22T02:08:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e9948610.1371/journal.pone.0099486Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.Sung Su YeaLomon SoSharmila MallyaJongdae LeeKamalakannan RajasekaranSubramaniam MalarkannanDavid A FrumanPhosphoinositide 3-kinases (PI3Ks) are promising targets for therapeutic development in cancer. The class I PI3K isoform p110α has received considerable attention in oncology because the gene encoding p110α (PIK3CA) is frequently mutated in human cancer. However, little is known about the function of p110α in lymphocyte populations that modulate tumorigenesis. We used recently developed investigational inhibitors to compare the function of p110α and other isoforms in natural killer (NK) cells, a key cell type for immunosurveillance and tumor immunotherapy. Inhibitors of all class I isoforms (pan-PI3K) significantly impaired NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity against tumor cells, whereas p110α-selective inhibitors had no effect. In NK cells stimulated through NKG2D, p110α inhibition modestly reduced PI3K signaling output as measured by AKT phosphorylation. Production of IFN-γ and NK cell-derived chemokines was blocked by a pan-PI3K inhibitor and partially reduced by a p110δinhibitor, with lesser effects of p110α inhibitors. Oral administration of mice with MLN1117, a p110α inhibitor in oncology clinical trials, had negligible effects on NK subset maturation or terminal subset commitment. Collectively, these results support the targeting of PIK3CA mutant tumors with selective p110α inhibitors to preserve NK cell function.http://europepmc.org/articles/PMC4051752?pdf=render |
| spellingShingle | Sung Su Yea Lomon So Sharmila Mallya Jongdae Lee Kamalakannan Rajasekaran Subramaniam Malarkannan David A Fruman Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS ONE |
| title | Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. |
| title_full | Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. |
| title_fullStr | Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. |
| title_full_unstemmed | Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. |
| title_short | Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. |
| title_sort | effects of novel isoform selective phosphoinositide 3 kinase inhibitors on natural killer cell function |
| url | http://europepmc.org/articles/PMC4051752?pdf=render |
| work_keys_str_mv | AT sungsuyea effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT lomonso effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT sharmilamallya effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT jongdaelee effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT kamalakannanrajasekaran effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT subramaniammalarkannan effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction AT davidafruman effectsofnovelisoformselectivephosphoinositide3kinaseinhibitorsonnaturalkillercellfunction |